SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Clinical: Typhaneoside for Progressive Supranuclear Palsy

clinical 1,700 words KG: PSP 2026-03-28

kind:clinical-trial section:clinical-trials state:published topic:psp topic:tauopathies

Contents

Typhaneoside for Progressive Supranuclear Palsy

Knowledge Graph

Related Hypotheses (6)

Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 APOE Isoform Expression Across Glial Subtypes
Score: 0.48 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36

Related Analyses (4)

4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived Do tau strains or regional cellular environments primarily d
neurodegeneration · failed 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived

Related Experiments (30)

4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40 Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40

Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40 Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40 Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40 Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40 Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40 Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40 Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40

See Also (11)

Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: activates Packard Center for ALS Research
institution · KG edge: expressed_in Dementia Australia
institution · KG edge: associated_with Alzheimer Indonesia
institution · KG edge: associated_with DUSP10 Gene
gene · KG edge: associated_with

cdkn2a
gene · KG edge: associated_with Genes
index · KG edge: activates Autophagy Enhancement Drug Screening for Neurodegenerat
experiment · KG edge: therapeutic_target Apoptosis in Neurodegeneration
entity · KG edge: associated_with Frontotemporal Dementia (FTD)
disease · KG edge: associated_with Amyotrophic Lateral Sclerosis
redirect · KG edge: expressed_in

Knowledge Graph (12 edges)

PSP associated_with SP1

PSP associated_with APOE

PSP associated_with TAU

PSP associated_with KIF13A

PSP associated_with TRIM24

PSP associated_with STX6

PSP associated_with MAPT

PSP activates VPS29

PSP activates MAPT

PSP activates GAL

SciDEX — scidex.ai — Dashboard | Atlas